Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$4.6M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$233M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Tade Brad L. | Nov 22, 2024 | Sell | 15,000 | $21.15 | $320,000 |
| Grossman Adam S | Nov 22, 2024 | Sell | 48,967 | $21.1 | $1M |
| Guiheen Lawrence P. | Sep 9, 2024 | Sell | 9,000 | $18.4654 | $170,000 |
| Kestenberg-Messina Kaitlin M. | Aug 30, 2024 | Sell | 24,150 | $16.8965 | $410,000 |
| Grossman Jerrold B | Aug 29, 2024 | Sell | 136,861 | $17.2725 | $2.4M |
| Grossman Adam S | Aug 27, 2024 | Sell | 389,356 | $17.2924 | $6.7M |
| Grossman Adam S | Aug 26, 2024 | Sell | 236,889 | $17.6922 | $4.2M |
| KWON YOUNG | Aug 23, 2024 | Sell | 60,000 | $18.26 | $1.1M |
| Grossman Adam S | Jun 14, 2024 | Sell | 100,000 | $10.7198 | $1.1M |
| ELMS STEVE | Mar 19, 2024 | Sell | 411,829 | $6.08 | $2.5M |
| ELMS STEVE | Mar 18, 2024 | Sell | 49,887 | $6.01 | $300,000 |
| ELMS STEVE | Mar 15, 2024 | Sell | 183,008 | $6.01 | $1.1M |
| ELMS STEVE | Mar 14, 2024 | Sell | 448,276 | $6.05 | $2.7M |
| ELMS STEVE | Mar 13, 2024 | Sell | 407,000 | $6.21 | $2.5M |
| Grossman Jerrold B | Aug 30, 2023 | Buy | 130,000 | $3.7088 | $480,000 |
| KWON YOUNG | Aug 24, 2023 | Buy | 25,000 | $3.9 | $98,000 |
| Fong Bryant | Aug 22, 2023 | Sell | 1,433,304 | $3.8685 | $5.5M |
| Grossman Adam S | Aug 18, 2023 | Sell | 250,000 | $4.1534 | $1M |
| LENZ BRIAN | Aug 16, 2023 | Sell | 178,184 | $4.4527 | $790,000 |
| Grossman Adam S | Aug 16, 2023 | Sell | 3 | $4.385 | $13 |
| Grossman Adam S | Aug 15, 2023 | Sell | 510,469 | $4.5428 | $2.3M |
| LENZ BRIAN | Aug 15, 2023 | Sell | 211,578 | $4.5975 | $970,000 |
What's the latest insider transaction for ADMA Biologics?
The most recent insider transaction for ADMA Biologics was conducted by Tade Brad L., who sold 15,000 shares on November 22, 2024 at a price of $21.15 per share.
Which insider bought the most ADMA stock over the last two years?
Grossman Jerrold B has bought the most ADMA stock in the last 2 years, with a total value of $480,000.
Which insider has sold the most ADMA stock over the last two years?
Grossman Adam S has sold the most ADMA stock in the last 2 years, with a total value of $16M.
What is the total value of insider transactions for ADMA Biologics (ADMA) in the last 2 years?
The total value of insider transactions for ADMA Biologics in the last 2 years is negative, amounting to -$37M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on ADMA Biologics' market confidence?
Over the last 2 years, insider transactions for ADMA Biologics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
